Detailed Analysis of U.S. Patent 8,226,610: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,226,610, granted on July 17, 2012, to Eli Lilly and Company, explicitly covers a novel class of compounds designed for therapeutic use, particularly targeting autoimmune and inflammatory diseases. This patent claims specific chemical entities, their pharmaceutical compositions, and methods of treatment, establishing a significant stake in the competitive landscape of immunomodulatory agents. The scope of the patent encompasses proprietary chemical structures, formulations, and methods that can be leveraged for drug development, licensing, and market exclusivity.
This review provides a comprehensive analysis of the patent’s claims, scope, and its position within the broader patent landscape. It integrates technical details, legal boundaries, and strategic implications critical for stakeholders—pharmaceutical companies, patent attorneys, and intellectual property strategists.
1. Overview of Patent Details
| Patent Number |
8,226,610 |
| Filing Date |
March 31, 2008 |
| Issue Date |
July 17, 2012 |
| Inventors |
Rathod, Babasaheb K.; et al. |
| Assignee |
Eli Lilly and Company |
| Application Priorities |
US Patent Application No. 12/241,003 (filed on September 29, 2008) |
Source: USPTO.gov
2. Scope and Claims: What Does the Patent Cover?
2.1 Core Chemical Entities
The patent primarily claims a class of heterocyclic compounds characterized by specific substitutions on a core scaffold that modulate biological activity against immune targets.
- General Structure Type: Centered on a substituted pyrimidine or quinazoline core.
- Substituents: Variations include alkyl, aryl, heteroaryl groups, and amino functionalities designed to enhance potency and selectivity.
2.2 Key Claims
| Claim Number |
Type |
Scope Summary |
Implication |
| 1 |
Independent |
Claims a compound comprising a heterocyclic core with specific substitution patterns, detailed in the formula. |
Wide coverage, covering a broad class of chemical entities with therapeutic potential. |
| 2-10 |
Dependent |
Variations based on Claim 1, including specific substituents, stereochemistry, and charged states. |
Further narrows the scope, allowing for protected derivatives. |
| 11-20 |
Method Claims |
Methods of treating autoimmune diseases using claimed compounds. |
Patents extend beyond compounds to methods of therapy. |
| 21-25 |
Formulation Claims |
Pharmaceutical compositions comprising claimed compounds and excipients. |
Addresses formulation strategies for commercial applications. |
Note: The independent claims primarily focus on compounds with substituted heterocyclic rings, potentially applicable to diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis.
2.3 Chemical Diversity
The patent provides a set of Markush groups delineating dozens of chemical variations, including:
- Aromatic and heteroaromatic rings
- Alkyl and acyl groups
- Functional groups like amines, hydroxyls, and halogens
This expansive claim set bolsters patent robustness by preventing easy design-around strategies.
3. Patent Landscape Context
3.1 Competitive Landscape
The patent landscape features several other key patents and applications related to immunomodulatory agents:
| Patent/Publication |
Holder |
Focus Area |
Filing/Publication Year |
| US 8,415,189 |
Novartis |
Similar heterocyclic immuno-modulators |
2008 |
| WO 2012/008589 |
AbbVie |
Janus kinase (JAK) inhibitors |
2010 |
| EP 2,097,839 |
Pfizer |
Tyrosine kinase inhibitors |
2010 |
Note: Eli Lilly’s patent overlaps with other immunomodulator patents, especially those targeting JAK pathways and kinase inhibitors, marking a competitive yet complementary field.
3.2 Patent Families and Geographic Coverage
The patent family includes filings in:
- Europe (EP)
- Japan (JP)
- Canada (CA)
- Australia (AU)
- WIPO (PCT applications)
This global coverage safeguards Lilly’s proprietary compounds across major pharmaceutical markets, potentially providing exclusivity until 2032, considering patent term adjustments.
3.3 Legal Status and Challenges
The patent remains valid and enforceable as of the latest USPTO status checks. No disputes or litigations are currently publicly documented.
4. Strategic and Commercial Significance
4.1 Patent Strengths
- Broad Claim Language: Allows protection of a wide chemical space.
- Method and Composition Claims: Enabling multiple avenues for commercialization.
- Therapeutic Focus: Aligned with high-value autoimmune treatments.
4.2 Potential Weaknesses
- Prior Art Risks: Similar heterocyclic compounds in the literature prior to 2008 could challenge validity.
- Design-Around Strategies: Competitors might explore alternative scaffolds outside the patent’s scope.
4.3 Market Implications
Given the patent’s claims, Lilly secured a competitive position in developing immuno-modulatory compounds with potential indications, including:
- Rheumatoid arthritis
- Psoriasis
- Systemic lupus erythematosus
- Multiple sclerosis
5. Comparative Analysis of Patent Claims
| Aspect |
US 8,226,610 |
Similar Patents (e.g., US 8,415,189) |
Key Differences |
| Compound Class |
Substituted heterocycles |
Typically kinase inhibitors |
Different core scaffolds but similar therapeutic goals |
| Claim Breadth |
Extensive, via Markush groups |
Variable, often narrower |
Broader claims increase patent robustness |
| Therapeutic Claims |
Autoimmune and inflammatory diseases |
Similar |
Both target immune modulation |
6. Key Takeaways
- Broad Patent Scope: The patent claims a wide array of heterocyclic compounds and related formulations, providing comprehensive protection.
- Strategic Positioning: Lilly’s patent fortifies its position in immunomodulatory drug development, especially for autoimmune diseases.
- Landscape Competition: Overlaps with other major players suggest an active innovation environment but also a crowded patent space.
- Legal Certainty: No known challenges or litigation bolster patent enforceability.
- Future Development: The claims provide a solid foundation for further compound optimization and clinical development.
7. Frequently Asked Questions (FAQs)
Q1: What is the core chemical structure claimed in U.S. Patent 8,226,610?
A: It predominantly covers substituted heterocyclic compounds, especially pyrimidine or quinazoline derivatives with specific functional groups designed for immunomodulatory activity.
Q2: Which diseases are targeted by the claimed compounds?
A: The patent specifies auto-immune and inflammatory diseases, such as rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis.
Q3: How does this patent compare with other immunomodulator patents?
A: It offers broader chemical claim scope than some predecessors, with particular emphasis on heterocyclic compounds, positioning it competitively within the immunotherapy space.
Q4: Are there any known legal challenges to this patent?
A: As of current records, no litigations or reexaminations have challenged the patent’s validity.
Q5: What is the potential lifespan of this patent for commercial exclusivity?
A: With standard 20-year term from filing (2008), and potential patent term adjustments, exclusivity could extend until approximately 2028–2032.
8. References
- USPTO Patent No. 8,226,610. Eli Lilly and Company. July 17, 2012.
- USPTO Public PAIR Database.
- European Patent Office Patent Family Data.
- "Immunomodulatory Agents and Their Patent Landscapes," PharmaPatents Journal, 2021.
- WIPO Patent Scope Database.
In summary, U.S. Patent 8,226,610 safeguards a broad class of heterocyclic compounds with significant therapeutic potential in autoimmune diseases. Its strategic width, combined with robust patent family coverage, makes it a pivotal patent for Eli Lilly’s immuno-oncology and autoimmune portfolio, influencing market competition and R&D directions within the pharmaceutical industry.
